A metaregression analysis of the dose-response effect of aspirin on stroke

Archives of Internal Medicine

Volumn 159, Issue 11, 1999, Pages 1248-1253

  Johnson, Eric S ^a   Lanes, Stephan F ^a   Wentworth III, Charles E ^a   Satterfield, Margaret H ^a   Abebe, Bethlehem L ^a   Dicker, Linda W ^a  

^a Epidemiology Resources Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; ASPIRIN; CEREBROVASCULAR DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK;

EID: 0033553874     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.11.1248     Document Type: Article

References (35)

1. Patrono C, Roth GJ. Aspirin in ischemic cerebrovascular disease: how strong is the case for a different dosing regimen? Stroke. 1996;27:756-760.
2. Barnett HJM, Kaste M, Meldrum H, Eliasziw M. Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts. Stroke. 1996;27:588-592.
3. Breddin K, Loew D, Lechner K, Uberla KK, Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis. 1980;9:325-344.
4. Breddin K, Loew D, Lechner K, Uberla KK, Walter E, on behalf of the German-Austrian Myocardial Infarction Study (GAMIS) Group. The German-Austrian Aspirin Trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation. 1980;62(suppl V): 63-72.
5. Überia K. Multicerter two-years prospective study on the prevention of second-ary myocardial infarction by ASA in comparison with phenprocoumon and placebo. In: Breddin K, Dorndorf W, Loew D, Marx R, eds. Acetylsalicylic Acid in Cerebral Ischaemia and Coronary Heart Disease. Stuttgart, Germany: Schattauer; 1978:159-169.
6. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977;8:301-316.
7. Lemak NA, Fields WS, Gary HEJ. Controlled trial of aspirin in cerebral ischemia: an addendum. Neurology. 1986;36:705-710.
8. Meister W, von Schacky C, Weber M, et al. Low-dose acetylsalicylic acid (100 mg/day) after aortocoronary bypass surgery: a placebo-controlled trial. Br J Clin Pharmacol. 1984;17:703-711.
9. Lorenz RL, von Schacky C, Weber M, et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation. Lancet. 1984;1:1261-1264.
10. UK-TIA Study Group. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: interim results. BMJ. 1988;296:316-320.
11. UK-TIA Study Group. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
12. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308:81-106.
13. Barnett HJM. Aspirin in stroke prevention: an overview. Stroke. 1990;21(suppl IV):IV40-IV43.
14. Cappelleri JC, Lau J, Kupelnick B, Chalmers TC. Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients: a metaregression analysis. Online J Curr Clin Trials [serial online]. March 14, 1995;doc 174.
15. Sze PC, Reitman D, Pincus MM, Sacks HS, Chalmers TC. Antiplatelet agents in the secondary prevention of stroke: meta-analysis of the randomized controlled trials. Stroke. 1988;19:436-442.
16. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry. 1996;60:197-199.
17. Lowenthal A, Buyse M. Secondary prevention of stroke: does dipyridamole add to aspirin? Acta Neurol Belg. 1994;94:24-34.
18. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med. 1995;332:238-248.
19. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
20. Bousser MG, Eschwege E, Haguenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke. 1983;14:5-14.
21. Britton M, Helmers C, Samuelsson K. High-dose acetylsalicylic acid after cerebral infarction: a Swedish co-operative study. Stroke. 1987;18:325-334.
22. Canadian Co-operative Study Group. A randomised trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:53-59.
23. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
24. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia, part II: surgical group. Stroke. 1978;9:309-318.
25. Gent M, Barnett HJM, Sackett DL, Taylor DW. A randomized trial of aspirin and sulfinpyrazone in patients with threatened stroke: results and methodologic issues. Circulation. 1980;62(suppl V):97-105.
26. Reuther R, Dorndorf W. Aspirin in patients with cerebral ischaemia and normal angiograms or non-surgical lesions. In: Breddin K, Dorndorf W, Loew D, Marx R, eds. Acetylsalicylic Acid in Cerebral Ischaemia and Coronary Heart Disease. Stuttgart. Germany: Schattauer; 1978:97-106.
27. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345-1349.
28. Sorensen PS, Pedersen H, Marquardsen J, et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks: a Danish cooperative study. Stroke. 1983;14:15-22.
29. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1998.
30. Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology. 1993;4:218-228.
31. Dyken ML, Barnett HJM, Easton D, et al. Low-dose aspirin and stroke: "It ain't necessarily so." Stroke. 1992;23:1395-1399.
32. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1988;296:320-331.
33. Hart RG, Harrison MJ. Aspirin wars: the optimal dose of aspirin to prevent stroke. Stroke. 1996;27:585-587.
34. Roderick PT, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol. 1993;35:219-226.
35. Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. Am J Epidemiol. 1987;125:761-768.